Two-centre experience of cannabidiol use in adults with Dravet syndrome

We describe real-world experience with cannabidiol (CBD) in adults with Dravet Syndrome (DS) via GW Pharma early access programme at two UK neurology centres. Adults with genetically-confirmed DS had CBD added to existing therapy, titrated up to 20mg/kg, as tolerated. The primary outcome measure was percentage reduction in convulsive seizures. Secondary outcome measures included changes in myoclonic seizures, and in cognition and quality of life as assessed by the Caregiver Global Impression of Change (CGIC), and incidence of adverse events (AEs).

Source: Seizure: European Journal of Epilepsy - May 22, 2021 Category: Neurology Authors: Katri Silvennoinen, Laura Mantoan Ritter, Lina Nashef, Kirsty Hudgell, Simona Balestrini, Sanjay M Sisodiya, Meneka K Sidhu Source Type: research